`
`
`
`May 2, 2014
`
`VIA ECF
`
`Hon. Joel A. Pisano, U.S.D.J.
`U.S. District Court for the District of New Jersey
`Clarkson S. Fisher Building & U.S. Courthouse
`402 East State Street
`Trenton, New Jersey 08608
`
`RE: Claim Construction for the ’285 Patent
`AstraZeneca AB, et al. v. Dr. Reddy’s Laboratories, Inc., et al.,
`Civ. Action No. 3:11-cv-02317-JAP-DEA;
`AstraZeneca AB, et al. v. Watson Laboratories, Inc. – Florida, et al.,
`Civ. Action No. 3:13-cv-03038-JAP-DEA; and
`AstraZeneca AB, et al. v. Mylan Pharmaceuticals Inc., et al.,
`Civ. Action No. 3:13-cv-04022-JAP-DEA_______________________
`
`
`Dear Judge Pisano:
`
`We write on behalf of Plaintiffs in the above-captioned ANDA matters.
`
`Pursuant to Paragraph 9 of the proposed Joint Scheduling Order agreed to by
`Plaintiffs and Defendants Mylan, Watson, and Lupin (see ECF Nos. 221 and 221-1
`filed in 3:11-cv-02317-JAP-DEA), Plaintiffs do not believe that any claim term from
`U.S. Patent No. 8,557,285 (the “’285 patent”) needs construction by the Court at this
`time. Instead, claim terms from the ’285 patent should be given their ordinary
`meaning or the meaning consistent with or already identified by the Court for claim
`terms from U.S. Patent No. 6,926,907 (see ECF No. 142 filed in 3:11-cv-02317-JAP-
`DEA). Any claim construction disputes may be addressed through summary
`judgment as the Court has previously held with respect to the ’907 patent (see ECF
`No. 165 filed in 3:11-cv-02317-JAP-DEA).
`
`
`
`Respectfully,
`
`s/ John E. Flaherty
`
`John E. Flaherty
`
`cc: Hon. Douglas E. Arpert, U.S.M.J. (via ECF)
` Counsel of Record (via email)
`
`Thank you for your consideration.
`
`John E. Flaherty
`Partner
`T. 973-639-7903
`F. 973-297-3971
`jflaherty@mccarter.com
`
`
`McCarter & English, LLP
`Four Gateway Center
`100 Mulberry Street
`Newark, NJ 07102-4056
`T. 973.622.4444
`F. 973.624.7070
`www.mccarter.com
`
`BOSTON
`
`HARTFORD
`
`NEW YORK
`
`NEWARK
`
`PHILADELPHIA
`
`STAMFORD
`
`WASHINGTON, DC
`
`WILMINGTON
`
`Page 1
`
`Dr. Reddy's Exh. 1018
`
`